Pandora, Gap Post R...
Health Care: Drugs
Transcept Pharmaceuticals Inc. (TSPT: NASDAQ)
$3.08 0.06 | 1.99%
05/23/13 - 04:00 PM ET
180.39K / 140.00K
Vol / Avg. Vol:3.00 / 3.02
Open / Prev. Close:2.93 - 3.10
Today's Range:2.87 - 7.45
52 Wk Range:-30.11%
Performance YTD:TheStreet Rating:
Portfolios with TSPT
- Portfolio NameUser Type
- ContributorStocks Under-$10 Moving Hig...
- ContributorBreakout Stocks Of The Week...
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Rising On Unusual Vo...
- ContributorStocks Rising On Unusual Vo...
- ContributorBreakout Stocks Of The Week...
- ContributorStocks With Big Insider Buy...
- UserGuitar.Picker
- Contributor10 Biotech Trades for Secon...
Latest TSPT Headlines from TheStreet
- Transcept Pharmaceuticals Management Discusses Q2 2012 Results - Earnings Call Transcript 08.13.12 | 07:08 pm
- 5 Biotech Stocks Poised for Breakouts 07.27.12 | 01:07 pm
- 8 Stocks Under $10 Skyrocketing Higher 07.19.12 | 01:07 pm
- Transcept Pharmaceuticals Inc. Stock Downgraded (TSPT) 05.16.12 | 05:05 am
- Transcept Stock Gaps Down On Today's Open (TSPT) 04.26.12 | 09:04 am
- Transcept Stock Hits New 52-Week High (TSPT) 04.09.12 | 04:04 pm
- 8 Stocks Rising on Huge Volume 03.19.12 | 12:03 pm
- Transcept Pharmaceuticals Inc. Stock Upgraded (TSPT) 03.16.12 | 05:03 am
- The Next Big Thing In Biotech: 2011 Review
12.16.11 | 07:12 am - Transcept Wins Sleeping Pill Approval 11.23.11 | 01:11 pm
Press Releases for TSPT
- Thomas J. Dietz, Ph.D., Appointed To The Transcept Pharmaceuticals Board Of Directors - PR Newswire 04.10.13 | 05:04 pm
- Transcept Pharmaceuticals To Present At Cowen And Company Health Care Conference On March 6 - PR Newswire 02.28.13 | 04:02 pm
- Transcept Pharmaceuticals To Present At Two Upcoming Investor Conferences - PR Newswire 02.05.13 | 07:02 pm
- Transcept Pharmaceuticals Comments On New FDA Dosage Reduction Requirements For Zolpidem Based Prescription Sleep Aids Administered At Bedtime - PR Newswire 01.10.13 | 09:01 pm
- Transcept Pharmaceuticals Announces That A Phase 2 Clinical Trial Of TO-2061 As Adjunctive Therapy For Obsessive Compulsive Disorder Did Not Meet Primary Endpoint - PR Newswire 12.21.12 | 07:12 am
- Transcept Pharmaceuticals To Host Conference Call To Discuss Broadened Intermezzo® Commercialization Strategy And New Consumer Advertising Campaign By Purdue Pharma - PR Newswire 11.26.12 | 06:11 pm
- Transcept Pharmaceuticals Announces Broadened Intermezzo® Commercialization Strategy Including Initiation Of A Direct To Consumer Advertising Campaign By Purdue Pharma - PR Newswire 11.26.12 | 06:11 pm
- Transcept Pharmaceuticals Completes Patient Enrollment In Phase 2 Clinical Trial Of TO-2061 Added As Adjunctive Therapy For Obsessive Compulsive Disorder - PR Newswire 09.12.12 | 07:09 am
- Transcept Pharmaceuticals To Present At The Rodman & Renshaw Global Investment Conference - PR Newswire 09.04.12 | 04:09 pm
- Transcept Pharmaceuticals Announces Listing Of New U.S. Patent For Intermezzo In FDA's Orange Book - PR Newswire 08.21.12 | 04:08 pm
Partner Headlines for TSPT
- New Data on Merck's Insomnia Drug - Analyst Blog - NASDAQ 09.17.12 | 11:09 pm
- New Data on Merck's Insomnia Drug - Analyst Blog - Zacks 09.17.12 | 07:09 pm
- Transcept Pharmaceuticals Inc. Enters Oversold Territory - Tale of the Tape - NASDAQ 09.17.12 | 02:09 pm
- AeroVironment REMAINS Compelling and 4 Active Stock Alerts You Must See - Wall St. Cheat Sheet 07.06.12 | 03:07 am
- Noteworthy Institutional 5% Ownership Filings On Friday - Seeking Alpha 04.02.12 | 08:04 am
- 3 Stocks With High Short Interest: 2 Buys, 1 Sell - Seeking Alpha 02.10.12 | 09:02 am
- Transcept's Intermezzo: A Blockbuster In The Making - Seeking Alpha 01.03.12 | 08:01 am
- End-of-Day Market Summary for December 21, 2011 - Benzinga 12.21.11 | 04:12 pm
- Transcept Pharmaceuticals Announces FDA Approval of Intermezzo For Use as Needed for the Treatment of Insomnia - Benzinga 11.23.11 | 01:11 pm
- Speculative Biotech: A Speculation Trader's Dream and Nightmare - Seeking Alpha 11.03.11 | 09:11 am
